The suitability of the HMGB1/sRAGE ratio as a diagnostic tool giving evidence for disease progression has been proven in multiple sclerosis patients, where serum and cerebral fluid measurements indicated an increase of the ratio, resulting from reduced sRAGE levels in diseased patients as compared to healthy control individuals [38]. This evidence concerns the gene HMGB1 and multiple sclerosis.